Consensus Twist Bioscience Corporation

Equities

TWST

US90184D1000

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
50.46 ^USD	-4.79%		+20.43%	+36.90%

Jun. 06	Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor	CI
Jun. 04	Guggenheim Initiates Twist Bioscience With Buy Rating, $53 Price Target	MT

Evolution of the average Target Price on Twist Bioscience Corporation

Price target over the last 5 years

History of analyst recommendation changes

6b39554ed6523732195582a3.l0UdhI-3WzZCre4Sw2mjmtF2V6qZODBOrAfSjIwrgUs.2TZQw_6aC104y79qpBHn-eIfLZ_7cHwslFGNydZz-CrfHVzD_OQ4YAvyow~cf33336a7ddaf6e1a4911f704d17d32e

Analyst Recommendations on Twist Bioscience Corporation

Guggenheim Initiates Twist Bioscience With Buy Rating, $53 Price Target	Jun. 04	MT
Scotiabank Adjusts Twist Bioscience's Price Target to $43 From $30, Maintains Sector Outperform Rating	Feb. 05	MT
Barclays Raises Price Target on Twist Bioscience to $45 From $30, Keeps Overweight Rating	Jan. 25	MT
Goldman Sachs Upgrades Twist Bioscience to Buy From Neutral, Raises Price Target to $45 From $25	Jan. 18	MT
Goldman Sachs Upgrades Twist Bioscience to Buy From Neutral, Price Target is $45	Jan. 17	MT
Evercore ISI Raises Twist Bioscience Price Target to $32 From $26, Maintains Outperform Rating	Nov. 17	MT
Berenberg Initiates Coverage on Twist Bioscience with Buy Rating, $27 Price Target	23-09-27	MT
Barclays Adjusts Price Target on Twist Bioscience to $26 From $20, Keeps Overweight Rating	23-08-07	MT
Barclays Adjusts Twist Bioscience Price Target to $26 From $20, Maintains Overweight Rating	23-08-07	MT
Goldman Sachs Adjusts Price Target on Twist Bioscience to $20 From $18, Maintains Neutral Rating	23-07-13	MT
Barclays Adjusts Price Target on Twist Bioscience to $20 From $32, Maintains Overweight Rating	23-05-08	MT
Baird Adjusts Twist Bioscience Price Target to $18 From $29, Maintains Outperform Rating	23-05-08	MT
Goldman Sachs Adjusts Price Target on Twist Bioscience to $20 From $43, Maintains Neutral Rating	23-04-18	MT
Goldman Sachs Adjusts Price Target on Twist Bioscience to $43 From $50, Maintains Neutral Rating	23-02-06	MT
Barclays Adjusts Price Target on Twist Bioscience to $32 From $37, Maintains Overweight Rating	23-02-06	MT
Baird Adjusts Price Target on Twist Bioscience to $29 From $33, Maintains Outperform Rating	23-02-06	MT
Barclays Adjusts Price Target on Twist Bioscience to $37 From $43, Maintains Overweight Rating	23-01-30	MT
Scotiabank Initiates Twist Bioscience at Outperform Rating With $33 Price Target	23-01-05	MT
Scotiabank Initiates Twist Bioscience at Sector Outperform With $33 Price Target	23-01-05	MT
Evercore ISI Upgrades Twist Bioscience to Outperform From In Line, Adjusts Price Target to $36 From $28	23-01-03	MT
SVB Securities Adjusts Twist Bioscience's Price Target to $30 From $45, Keeps Market Perform Rating	22-11-21	MT
Baird Adjusts Price Target on Twist Bioscience to $33 From $56, Maintains Outperform Rating	22-11-21	MT
Barclays Trims Price Target on Twist Bioscience to $43 From $45, Maintains Overweight Rating	22-11-21	MT
SVB Securities Adjusts Twist Bioscience's Price Target to $45 From $50, Maintains Market Perform Rating	22-10-07	MT
Barclays Adjusts Price Target on Twist Bioscience to $45 From $55, Reiterates Overweight Rating	22-10-06	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

50.46 USD

Average target price

44.44 USD

Spread / Average Target

-11.92%

High Price Target

55 USD

Spread / Highest target

+9.00%

Low Price Target

28 USD

Spread / Lowest Target

-44.51%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Twist Bioscience Corporation

Guggenheim
Scotiabank
Barclays
Goldman Sachs
Evercore ISI
Berenberg Bank
Baird
SVB Securities LLC
JPMorgan Chase
SVB Leerink
William Blair & Co.
Piper Sandler
J.P. Morgan Chase

Ratings for Twist Bioscience Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar